Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
A phase 3 trial of Cemiplimab in cutaneous squamous cell carcinoma, run by Regeneron Pharmaceuticals, now recruiting.
Overview
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT06585410 by Regeneron Pharmaceuticals, with 369 participants planned, started 2025-01-02 and due to reach its primary completion in 2030-05-03. Interventions recorded: Cemiplimab, Standard of care. Conditions listed: Cutaneous Squamous Cell Carcinoma (CSCC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small
Shares Cemiplimab, Regeneron.
- TrialA Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta
Shares Cemiplimab, Regeneron.
- TrialREGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate
Shares Cemiplimab, Regeneron.
- TrialA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Hav
Shares Cemiplimab, Regeneron.
- TrialStudy Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
- TrialA Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Shares Cemiplimab, Regeneron.
- TrialA Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous
Shares Cemiplimab, Regeneron.
- TrialEMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9
Shares Cemiplimab, Regeneron.